A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer
Tomoko Kodama,Takashi Imajima,Mototsugu Shimokawa,Taiga Otsuka,Masahiro Kawahira,Junichi Nakazawa,Takeshi Hori,Taro Shibuki,Shiho Arima,Akio Ido,Keisuke Miwa,Yoshinobu Okabe,Futa Koga,Yujiro Ueda,Yoshihito Kubotsu,Hozumi Shimokawa,Shigeyuki Takeshita,Kazuo Nishikawa,Azusa Komori,Satoshi Otsu,Ayumu Hosokawa,Tatsunori Sakai,Kenji Sakai,Hisanobu Oda,Machiko Kawahira,Shuji Arita,Takuya Honda,Hiroki Taguchi,Kengo Tsuneyoshi,Yasunori Kawaguchi,Toshihiro Fujita,Takahiro Sakae,Tsuyoshi Shirakawa,Toshihiko Mizuta,Kenji Mitsugi
DOI: https://doi.org/10.1038/s41598-024-63172-y
IF: 4.6
2024-05-31
Scientific Reports
Abstract:Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard regimen after gemcitabine-based therapy for patients with unresectable or recurrent pancreatic cancer. However, there are limited clinical data on its efficacy and safety in the real-world. We therefore initiated a retrospective and prospective observational study (NAPOLEON-2). The results of the retrospective part were reported herein. In this retrospective study, we evaluated 161 consecutive patients who received NFF as second-or-later-line regimen. The main endpoint was overall survival (OS), and the other endpoints were response rate, disease control rate, progression-free survival (PFS), dose intensity, and adverse events (AEs). The median age was 67 years (range, 38–85 years). The median OS and PFS were 8.1 and 3.4 months, respectively. The objective response and disease control rates were 5% and 52%, respectively. The median relative dose intensity was 81.6% for nanoliposomal irinotecan and 82.9% for fluorouracil. Grade 3 or 4 hematological and nonhematological AEs occurred in 47 and 42 patients, respectively. Common grade 3 or 4 AEs included neutropenia (24%), anorexia (12%), and leukocytopenia (12%). Subanalysis of patients treated with second-line and third-or-later-line demonstrated no statistical significant difference in OS (7.6 months vs. 9.1 months, respectively; hazard ratio, 0.92; 95% confidence interval, 0.64–1.35; p = 0.68). In conclusion, NFF has acceptable efficacy and safety profile even in real-world clinical settings. The prospective study is in progress to validate these findings.
multidisciplinary sciences